Last updated: 15 June 2019 at 2:02am EST

Wilfred Ethree Arch Managem... Net Worth




The estimated Net Worth of Wilfred Ethree Arch Managem... is at least $19.9 Миллион dollars as of 10 September 2015. Wilfred Managem owns over 120,000 units of Concert Pharmaceuticals Inc stock worth over $6,227 and over the last 9 years Wilfred sold CNCE stock worth over $19,920,420.

Wilfred Managem CNCE stock SEC Form 4 insiders trading

Wilfred has made over 6 trades of the Concert Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Wilfred sold 68,854 units of CNCE stock worth $1,378,457 on 14 December 2015.

The largest trade Wilfred's ever made was selling 760,000 units of Concert Pharmaceuticals Inc stock on 14 August 2015 worth over $12,015,600. On average, Wilfred trades about 201,285 units every 21 days since 2015. As of 10 September 2015 Wilfred still owns at least 744 units of Concert Pharmaceuticals Inc stock.

You can see the complete history of Wilfred Managem stock trades at the bottom of the page.



Insiders trading at Concert Pharmaceuticals Inc

Over the last 11 years, insiders at Concert Pharmaceuticals Inc have traded over $69,766,120 worth of Concert Pharmaceuticals Inc stock and bought 1,926,078 units worth $25,219,472 . The most active insiders traders include Plc Gsk, Associates Gp Llcqvt Fund V... и Partners L P/Ilbiotechnolog.... On average, Concert Pharmaceuticals Inc executives and independent directors trade stock every 28 days with the average trade being worth of $447,820. The most recent stock trade was executed by Nancy Stuart on 15 February 2023, trading 6,048 units of CNCE stock currently worth $50,380.



What does Concert Pharmaceuticals Inc do?

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert's lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates.



What does Concert Pharmaceuticals Inc's logo look like?

Concert Pharmaceuticals Inc logo

Complete history of Wilfred Managem stock trades at Concert Pharmaceuticals Inc

Дата
#
Компания
инсайдер
Транзакция
Транзакция
Акции Цена за акцию Общая стоимость Акции после Источник
14 Dec 2015 Wilfred Ethree Arch Managem...
Продажа 68,854 $20.02 $1,378,457
14 Dec 2015
0
14 Dec 2015 Wilfred Ethree Arch Managem...
Продажа 68,854 $20.02 $1,378,457
14 Dec 2015
0
10 Sep 2015 Wilfred Ethree Arch Managem...
Продажа 120,000 $18.22 $2,186,400
10 Sep 2015
744
14 Aug 2015 Wilfred Ethree Arch Managem...
Продажа 760,000 $15.81 $12,015,600
14 Aug 2015
2,040
13 Aug 2015 Wilfred Ethree Arch Managem...
Продажа 92,215 $16.75 $1,544,601
13 Aug 2015
10,249
12 Aug 2015 Wilfred Ethree Arch Managem...
Продажа 97,785 $14.49 $1,416,905
12 Aug 2015
11,245


Concert Pharmaceuticals Inc executives and stock owners

Concert Pharmaceuticals Inc executives and other stock owners filed with the SEC include: